This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Intensifying Lipid-Lowering Therapy With PCSK9 Inhibitors

Intensifying Lipid-Lowering Therapy With PCSK9 Inhibitors

Format

Patient Case Study

Time to Complete

30 minutes

Released

February 16, 2018

Expires

February 16, 2019
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider

This educational activity is jointly provided by American Academy of CME, Inc. and Spire Learning.

Commercial Supporter

This activity is supported by educational funding provided by Amgen.

Program Description

This interactive, on-demand activity introduces AR, a 69-year-old man with hypertension and hypercholesterolemia who is concerned about his long-term health and wants to reduce his cardiovascular risk. In 30 minutes, you can review this case-based-activity and learn about:

  • Lifestyle interventions to help lower LDL-cholesterol
  • ACC/AHA Blood Cholesterol Guideline recommendations for treating atherosclerotic cardiovascular disease (ASCVD)
  • How to evaluate the efficacy and safety of lipid-lowering therapy
  • The appropriate use of statins to achieve target LDL-C levels
  • When to consider initiating PCSK9 inhibitor therapy for at-risk individuals
  • How you can help your patients achieve their LDL-C and risk-reduction goals

Intended Audience

This activity has been designed to meet the educational needs of cardiologists, interventional cardiologists, and other clinicians with an interest in the management of hypercholesterolemia.

Learning Objectives

At the conclusion of this educational activity, participants should be better able to:

  • Interpret clinical trial data evaluating the efficacy and safety of lipid-lowering therapy in patients with ASCVD
  • Describe how PCSK9 inhibition enhances LDL-C reduction in patients with hypercholesterolemia
  • Determine when PCSK9 inhibitor therapy should be considered for at-risk individuals

Conflict Of Interest Disclosure Policy

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Faculty

Ty J. Gluckman, MD, FACC, FAHA
Medical Director, Clinical Transformation
Providence Heart and Vascular Institute
Portland, OR
Adjunct Faculty, Ciccarone Center for the Prevention of Heart Disease
The Johns Hopkins Hospital
Baltimore, MD

Dr. Gluckman discloses the following:
Consultant – for marketing purposes: Boehringer Ingelheim

Accredited Provider Disclosures

INDEPENDENT CLINICAL PEER REVIEWER
Matthew C. Weiss, MD
, has no relevant financial relationships with any commercial interests.

PLANNERS
AMERICAN ACADEMY OF CME, INC.
John JD Juchniewicz, MCIS, CHCP
, has no relevant financial relationships with any commercial interests.

SPIRE LEARNING
Aisha Cobbs, PhD
, has no relevant financial relationships with any commercial interests.
Lisa Conklin has no relevant financial relationships with any commercial interests.
Lauren Waters has no relevant financial relationships with any commercial interests.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc. (Academy) and Spire Learning. American Academy of CME, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

American Academy of CME, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity does not contain discussion of published and/or investigational uses of agents that are not indicated by the FDA for the treatment of hypercholesterolemia. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Further, participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this activity.

Disclaimer

The opinions expressed in this educational activity are those of the faculty author and do not represent those of Academy or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

Levels of Evidence




Source: American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Instructions

This activity has no fee and should take approximately 30 minutes to complete. Participants should first read the learning objectives and other introductory CME information. This program consists of a case-based narrative with interactive participant questions and expert commentary. To receive credit, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have printed a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time. Credit for this activity will be available from February 16, 2018, through February 16, 2018.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue